Acrux Limited (ARUXF)
USD 0.04
(0.0%)
USD 0.04
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | -5.8 Million AUD | -659.16% |
| 2023 | -764 Thousand AUD | 92.23% |
| 2022 | -9.83 Million AUD | 22.13% |
| 2021 | -12.62 Million AUD | -33.34% |
| 2020 | -9.47 Million AUD | -13.77% |
| 2019 | -8.32 Million AUD | 41.3% |
| 2018 | -14.18 Million AUD | -5736.21% |
| 2017 | -243 Thousand AUD | -101.87% |
| 2016 | 12.98 Million AUD | 16.63% |
| 2015 | 11.13 Million AUD | -60.21% |
| 2014 | 27.97 Million AUD | 303.84% |
| 2013 | 6.92 Million AUD | -6.29% |
| 2012 | 7.39 Million AUD | -87.07% |
| 2011 | 57.14 Million AUD | 22.76% |
| 2010 | 46.55 Million AUD | 703.34% |
| 2009 | -7.71 Million AUD | -53.52% |
| 2008 | -5.02 Million AUD | 36.06% |
| 2007 | -7.86 Million AUD | 20.93% |
| 2006 | -9.94 Million AUD | -41577.15% |
| 2005 | 23.96 Thousand AUD | 901.77% |
| 2004 | -2989.00 AUD | 70.15% |
| 2003 | -10.01 Thousand AUD | 99.68% |
| 2002 | -3.14 Million AUD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 FY | -5.8 Million AUD | -659.16% |
| 2024 Q2 | -3.23 Million AUD | -228.02% |
| 2024 Q4 | -2.56 Million AUD | 20.93% |
| 2023 Q4 | 2.53 Million AUD | 176.81% |
| 2023 Q2 | -3.29 Million AUD | 24.47% |
| 2023 FY | -764 Thousand AUD | 92.23% |
| 2022 FY | -9.83 Million AUD | 22.13% |
| 2022 Q4 | -4.36 Million AUD | 20.32% |
| 2022 Q2 | -5.47 Million AUD | -13.01% |
| 2021 Q4 | -4.84 Million AUD | 37.8% |
| 2021 FY | -12.62 Million AUD | -33.34% |
| 2021 Q2 | -7.78 Million AUD | -156.46% |
| 2020 FY | -9.47 Million AUD | -13.77% |
| 2020 Q4 | -3.03 Million AUD | 52.82% |
| 2020 Q2 | -6.43 Million AUD | -34.37% |
| 2019 FY | -8.32 Million AUD | 41.3% |
| 2019 Q2 | -3.53 Million AUD | 35.57% |
| 2019 Q4 | -4.78 Million AUD | -35.44% |
| 2018 Q2 | -8.69 Million AUD | -32.43% |
| 2018 Q4 | -5.48 Million AUD | 36.88% |
| 2018 FY | -14.18 Million AUD | -5736.21% |
| 2017 FY | -243 Thousand AUD | -101.87% |
| 2017 Q4 | -6.56 Million AUD | -203.84% |
| 2017 Q2 | 6.32 Million AUD | 95.43% |
| 2016 Q4 | 3.23 Million AUD | -66.81% |
| 2016 FY | 12.98 Million AUD | 16.63% |
| 2016 Q2 | 9.74 Million AUD | 137.01% |
| 2015 FY | 11.13 Million AUD | -60.21% |
| 2015 Q4 | 4.11 Million AUD | -41.41% |
| 2015 Q2 | 7.01 Million AUD | 107.63% |
| 2014 Q4 | 3.38 Million AUD | -86.25% |
| 2014 FY | 27.97 Million AUD | 303.84% |
| 2014 Q2 | 24.59 Million AUD | 380.84% |
| 2013 Q4 | 5.11 Million AUD | 182.23% |
| 2013 Q2 | 1.81 Million AUD | 0.0% |
| 2013 FY | 6.92 Million AUD | -6.29% |
| 2012 Q4 | - AUD | 0.0% |
| 2012 FY | 7.39 Million AUD | -87.07% |
| 2011 FY | 57.14 Million AUD | 22.76% |
| 2011 Q4 | - AUD | 0.0% |
| 2010 Q4 | - AUD | 0.0% |
| 2010 FY | 46.55 Million AUD | 703.34% |
| 2009 FY | -7.71 Million AUD | -53.52% |
| 2009 Q4 | - AUD | 0.0% |
| 2008 Q4 | - AUD | 0.0% |
| 2008 FY | -5.02 Million AUD | 36.06% |
| 2007 FY | -7.86 Million AUD | 20.93% |
| 2007 Q4 | - AUD | 0.0% |
| 2006 Q4 | - AUD | 0.0% |
| 2006 FY | -9.94 Million AUD | -41577.15% |
| 2005 FY | 23.96 Thousand AUD | 901.77% |
| 2005 Q4 | - AUD | 0.0% |
| 2004 Q4 | - AUD | 0.0% |
| 2004 FY | -2989.00 AUD | 70.15% |
| 2003 FY | -10.01 Thousand AUD | 99.68% |
| 2002 FY | -3.14 Million AUD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Capstone Therapeutics Corp. | -3.81 Million USD | -51.872% |
| Skye Bioscience, Inc. | -37.64 Million USD | 84.593% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 108.905% |
| Nascent Biotech, Inc. | -2.08 Million USD | -177.82% |
| Qrons Inc. | -789.34 Thousand USD | -634.785% |
| Adynxx, Inc. | - USD | Infinity% |
| BioStem Technologies, Inc. | -8.48 Million USD | 31.628% |
| CSL Limited | 2.64 Billion USD | 100.22% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 110.948% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 16.939% |
| Regen BioPharma, Inc. | 1.02 Million USD | 666.679% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 90.735% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -1295.979% |
| Rebus Holdings, Inc. | -1.02 Million USD | -468.627% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -334.317% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -817.131% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 63.456% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 92.263% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 11.802% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -2021.418% |
| SQZ Biotechnologies Company | -79.46 Million USD | 92.701% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -100.526% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -218.589% |
| Mesoblast Limited | -87.95 Million USD | 93.406% |
| Marizyme, Inc. | -65.34 Million USD | 91.124% |
| Genus plc | 7.9 Million USD | 173.418% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 46.749% |
| Pharming Group N.V. | -10.54 Million USD | 45.013% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -167.304% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -56.324% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 34.419% |
| ContraFect Corporation | -65.15 Million USD | 91.098% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | -18.705% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -235.754% |
| IMV Inc. | -36.48 Million USD | 84.103% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 28.037% |
| MultiCell Technologies, Inc. | -380.07 USD | -1525934.678% |
| ONE Bio Corp. | 8.67 Million USD | 166.846% |
| Accustem Sciences Inc. | -3.74 Million USD | -54.815% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 88.78% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | -357.726% |
| Q BioMed Inc. | -2.05 Million USD | -182.638% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -55.371% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -143.608% |
| Biomind Labs Inc. | -1.21 Million USD | -377.634% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 90.289% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -86.99% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 26.611% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -197.55% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -38628.632% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 0.297% |
| GB Sciences, Inc. | -1.36 Million USD | -325.945% |
| Alpha Cognition Inc. | -13.77 Million USD | 57.887% |
| HST Global, Inc. | -146.21 Thousand USD | -3866.897% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -230.527% |
| Halberd Corporation | -79.67 Thousand USD | -7179.482% |
| Enzolytics Inc. | -2.17 Million USD | -166.442% |
| Agentix Corp. | -1.37 Million USD | -322.06% |
| Resverlogix Corp. | -3.61 Million USD | -60.665% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | -82.882% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 98.034% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 6018.367% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 183.759% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | -45.986% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -91.664% |
| AVAX Technologies, Inc. | -6.41 Million USD | 9.568% |
| Zenith Capital Corp. | -10.59 Million USD | 45.262% |
| Genscript Biotech Corporation | -95.47 Million USD | 93.925% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -24854.823% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | -39.896% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -9496.197% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -189.26% |
| Kadimastem Ltd | -3.3 Million USD | -75.364% |
| Helix BioMedix, Inc. | -1.05 Million USD | -449.213% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -1214.093% |
| LadRx Corporation | 400.44 Thousand USD | 1548.396% |
| Cell Source, Inc. | -5.32 Million USD | -8.998% |
| Regen BioPharma, Inc. | 1.02 Million USD | 666.679% |
| NovAccess Global Inc. | -4.76 Million USD | -21.614% |
| Affymax, Inc. | -14.42 Million USD | 59.789% |
| Itoco Inc. | -1.86 Million USD | -210.327% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | -30.556% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -247.513% |
| Mobile Lads Corp. | -2.26 Million USD | -156.264% |
| CytoDyn Inc. | -49.84 Million USD | 88.363% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -7238.707% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -2442.443% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -516.019% |
| SYBLEU INC | -180.3 Thousand USD | -3116.789% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -259.637% |
| International Stem Cell Corporation | -131 Thousand USD | -4327.481% |
| Bioxytran, Inc. | -4.28 Million USD | -35.514% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -10586.91% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -129.227% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 87.935% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -174.361% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -642.745% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -83.081% |
| Neutra Corp. | -233.46 Thousand USD | -2384.312% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 71.416% |
| PureTech Health plc | -65.69 Million USD | 91.172% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 72.727% |
| IXICO plc | -1.17 Million USD | -392.36% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 41.573% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 89.847% |
| CSL Limited | 2.64 Billion USD | 100.22% |
| Cellectis S.A. | -103.17 Million USD | 94.378% |